Why is Concord Biotech falling/rising?

As of 17-Sep, Concord Biotech Ltd's stock price is currently at 1,636.15, reflecting an increase of 11.15, or 0.69%. Despite this positive movement today, the stock has shown a negative performance over the past week and month, with declines of 0.84% and 0.07%, respectively. The stock's year-to-date return is notably poor at -25.97%, and it has underperformed the benchmark Sensex, which has gained 5.83% in the same period. Today's performance indicates that the stock has outperformed its sector by 0.65%, but it is important to note that investor participation is declining, with a significant drop in delivery volume. The company boasts a high management efficiency with a return on equity (ROE) of 19.76% and a low debt-to-equity ratio, yet it faces challenges such as a substantial decline in profit after tax and net sales, contributing to a perception of poor long-term growth.
In the broader market context, while Concord Biotech's stock has risen slightly today, it continues to lag behind the Sensex, which has performed better over the short term. The stock's negative returns over the past year and its underperformance compared to the BSE500 in various time frames highlight ongoing concerns among investors. Additionally, the decrease in institutional investor participation, which is critical for stock stability and growth, further exacerbates the stock's challenges. Overall, despite today's modest gain, the underlying fundamentals and market sentiment suggest a cautious outlook for Concord Biotech moving forward.